Ibio Inc at JMP Securities Life Sciences Conference Transcript
Thank you everybody joining us again at the JMP Securities Life Sciences Conference. My name is Roy Buchanan, one of the biotech equity analysts. Our next company we're happy to have is iBio. And we have Martin Brenner, who's the Chief Scientific Officer and Interim Chief Executive Officer. So, thank you for joining us, Martin.
Thanks for having us. Really good to see you in person for the first time.
Questions & Answers
Yes, good to see you too. So maybe the company has undergone quite a transformation recently, still undergoing a transformation, just maybe lay out for us how the company is structured today? How many people do you have in R&D? I'm following the acquisition of RubrYc, especially directed at the discovery platform? And what are your core areas of investigation today?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |